Aura Biosciences (AURA) Financials

$5.38 -0.14 (-2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$5.38 0.00 (0.00%)

As of 04:27 PM Eastern

Annual Income Statements for Aura Biosciences

This table shows Aura Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-59	-76	-87
Consolidated Net Income / (Loss)	-59	-76	-87
Net Income / (Loss) Continuing Operations	-59	-76	-87
Total Pre-Tax Income	-59	-76	-87
Total Operating Income	-60	-85	-96
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	60	85	96
Selling, General & Admin Expense	18	20	23
Research & Development Expense	42	65	73
Total Other Income / (Expense), net	1.53	8.72	9.31
Interest Expense	-1.86	-8.59	-9.43
Other Income / (Expense), net	-0.33	0.13	-0.12
Income Tax Expense	0.00	0.14	0.11
Basic Earnings per Share	($1.96)	($1.93)	($1.75)
Weighted Average Basic Shares Outstanding	29.94M	39.62M	49.65M
Diluted Earnings per Share	($1.96)	($1.93)	($1.75)
Weighted Average Diluted Shares Outstanding	29.94M	39.62M	49.65M
Weighted Average Basic & Diluted Shares Outstanding	37.80M	49.50M	50.23M

This table shows Aura Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-16	-17	-17	-18	-19	-22	-20	-20	-21	-26
Consolidated Net Income / (Loss)	-16	-17	-17	-18	-19	-22	-20	-20	-21	-26
Net Income / (Loss) Continuing Operations	-16	-17	-17	-18	-19	-22	-20	-20	-21	-26
Total Pre-Tax Income	-16	-17	-17	-18	-19	-22	-20	-20	-21	-26
Total Operating Income	-16	-18	-19	-20	-20	-25	-22	-23	-23	-28
Total Operating Expenses	16	18	19	20	20	25	22	23	23	28
Selling, General & Admin Expense	4.76	4.45	5.04	5.16	5.06	4.50	5.26	5.88	6.20	5.47
Research & Development Expense	11	13	14	15	15	20	17	17	17	22
Total Other Income / (Expense), net	0.15	1.05	1.98	1.98	1.98	2.79	2.65	2.43	2.23	2.00
Interest Expense	-0.48	-1.06	-1.99	-2.01	-1.98	-2.61	-2.69	-2.45	-2.26	-2.04
Other Income / (Expense), net	-0.33	-0.01	-0.01	-0.03	-0.01	0.18	-0.03	-0.03	-0.03	-0.04
Income Tax Expense	-	-	0.00	0.00	0.00	0.14	0.05	0.00	0.04	0.02
Basic Earnings per Share	($0.54)	($0.52)	($0.46)	($0.48)	($0.48)	($0.51)	($0.40)	($0.41)	($0.42)	($0.52)
Weighted Average Basic Shares Outstanding	29.27M	29.94M	37.78M	37.86M	38.19M	39.62M	49.45M	49.55M	49.66M	49.65M
Diluted Earnings per Share	($0.54)	($0.52)	($0.46)	($0.48)	($0.48)	($0.51)	($0.40)	($0.41)	($0.42)	($0.52)
Weighted Average Diluted Shares Outstanding	29.27M	29.94M	37.78M	37.86M	38.19M	39.62M	49.45M	49.55M	49.66M	49.65M
Weighted Average Basic & Diluted Shares Outstanding	29.33M	37.80M	37.80M	38.20M	38.26M	49.50M	49.54M	49.61M	49.95M	50.23M

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-27	-81	-9.39
Net Cash From Operating Activities	-55	-64	-80
Net Cash From Continuing Operating Activities	-55	-64	-80
Net Income / (Loss) Continuing Operations	-59	-76	-87
Consolidated Net Income / (Loss)	-59	-76	-87
Depreciation Expense	1.18	1.30	1.22
Non-Cash Adjustments To Reconcile Net Income	6.09	6.83	8.54
Changes in Operating Assets and Liabilities, net	-3.10	4.44	-2.65
Net Cash From Investing Activities	-68	-114	69
Net Cash From Continuing Investing Activities	-68	-114	69
Purchase of Property, Plant & Equipment	-1.09	-0.71	-1.25
Purchase of Investments	-120	-234	-59
Sale and/or Maturity of Investments	53	120	129
Net Cash From Financing Activities	96	97	1.60
Net Cash From Continuing Financing Activities	96	97	1.60
Issuance of Common Equity	95	96	0.18
Other Financing Activities, net	0.43	1.38	1.42

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	7.29	60	-83	9.24	7.85	-15	-15	3.80	-4.67	6.29
Net Cash From Operating Activities	-11	-18	-16	-15	-15	-17	-24	-16	-15	-24
Net Cash From Continuing Operating Activities	-11	-17	-16	-15	-15	-17	-24	-16	-15	-24
Net Income / (Loss) Continuing Operations	-16	-17	-17	-18	-19	-22	-20	-20	-21	-26
Consolidated Net Income / (Loss)	-16	-17	-17	-18	-19	-22	-20	-20	-21	-26
Depreciation Expense	0.30	0.32	0.33	0.30	0.34	0.32	0.31	0.31	0.31	0.29
Non-Cash Adjustments To Reconcile Net Income	1.72	1.20	1.02	1.21	2.20	2.39	1.52	2.41	2.08	2.53
Changes in Operating Assets and Liabilities, net	2.46	-2.45	-0.30	1.89	0.81	2.03	-6.57	1.49	3.38	-0.94
Net Cash From Investing Activities	18	-17	-67	21	22	-90	9.40	20	9.89	30
Net Cash From Continuing Investing Activities	18	-17	-67	21	22	-90	9.27	20	9.89	30
Purchase of Property, Plant & Equipment	-0.06	-0.36	-0.12	-0.18	-0.09	-0.32	-0.21	-0.40	-0.34	-0.30
Sale and/or Maturity of Investments	18	32	22	22	22	55	39	30	30	30
Net Cash From Financing Activities	0.10	95	0.20	2.48	1.63	93	0.25	0.08	0.72	0.54
Net Cash From Continuing Financing Activities	0.10	95	0.20	2.48	1.63	93	0.25	0.08	0.72	0.54
Other Financing Activities, net	0.10	-	0.15	0.66	0.20	0.37	0.16	0.08	0.63	0.54

This table presents Aura Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	224	255	183
Total Current Assets	197	232	161
Cash & Equivalents	122	41	32
Restricted Cash	0.02	0.02	0.00
Short-Term Investments	67	185	119
Prepaid Expenses	7.87	5.63	9.53
Plant, Property, & Equipment, net	5.37	3.15	3.22
Total Noncurrent Assets	22	20	19
Other Noncurrent Operating Assets	21	19	18
Other Noncurrent Nonoperating Assets	0.77	0.77	0.77
Total Liabilities & Shareholders' Equity	224	255	183
Total Liabilities	28	29	31
Total Current Liabilities	10	12	15
Accounts Payable	2.92	1.79	2.30
Accrued Expenses	4.57	7.88	9.46
Other Current Liabilities	2.96	2.69	3.15
Total Noncurrent Liabilities	18	17	16
Other Noncurrent Operating Liabilities	18	17	16
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	196	226	152
Total Preferred & Common Equity	196	226	152
Total Common Equity	196	226	152
Common Stock	407	513	526
Retained Earnings	-211	-287	-374
Accumulated Other Comprehensive Income / (Loss)	-0.07	0.54	0.26

This table presents Aura Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	143	206	193	180	235	218	205
Total Current Assets	116	179	166	154	212	196	183
Cash & Equivalents	61	38	48	56	26	30	25
Restricted Cash	0.18	0.02	0.02	0.02	0.00	0.00	0.00
Short-Term Investments	50	135	114	93	177	157	149
Prepaid Expenses	4.21	5.58	4.18	4.81	9.38	8.18	9.10
Plant, Property, & Equipment, net	5.48	5.17	5.06	4.86	3.05	3.33	3.33
Total Noncurrent Assets	22	22	21	21	20	19	19
Other Noncurrent Operating Assets	21	21	21	20	19	19	18
Other Noncurrent Nonoperating Assets	0.77	0.77	0.77	0.77	0.77	0.77	0.77
Total Liabilities & Shareholders' Equity	143	206	193	180	235	218	205
Total Liabilities	28	26	26	28	26	27	31
Total Current Liabilities	9.96	8.11	8.90	11	9.66	11	15
Accounts Payable	1.72	1.06	0.55	1.49	1.93	1.46	1.99
Accrued Expenses	5.30	4.07	5.33	6.37	4.99	6.34	9.60
Other Current Liabilities	2.94	2.99	3.01	3.04	2.74	2.75	3.13
Total Noncurrent Liabilities	18	18	17	17	17	16	16
Other Noncurrent Operating Liabilities	18	18	17	17	17	16	16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	115	180	166	152	209	191	175
Total Preferred & Common Equity	115	180	166	152	209	191	175
Total Common Equity	115	180	166	152	209	191	175
Common Stock	310	409	413	417	516	519	522
Retained Earnings	-194	-228	-247	-265	-307	-327	-348
Accumulated Other Comprehensive Income / (Loss)	-0.15	-0.05	-0.22	-0.13	0.02	-0.18	0.61

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-72.71%	-40.56%	-13.70%
EBIT Growth	-71.98%	-39.97%	-13.41%
NOPAT Growth	-71.05%	-40.96%	-13.09%
Net Income Growth	-66.70%	-30.03%	-13.76%
EPS Growth	78.10%	1.53%	9.33%
Operating Cash Flow Growth	-68.47%	-16.93%	-24.99%
Free Cash Flow Firm Growth	-74.06%	-16.27%	-30.63%
Invested Capital Growth	92.78%	-118.20%	109.92%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-24.84%	-9.11%	-3.57%
EBIT Q/Q Growth	-24.48%	-8.96%	-3.49%
NOPAT Q/Q Growth	-24.63%	-9.21%	-3.25%
Net Income Q/Q Growth	-9.15%	-7.87%	-4.45%
EPS Q/Q Growth	-102.92%	0.52%	-0.57%
Operating Cash Flow Q/Q Growth	-12.18%	0.97%	-8.96%
Free Cash Flow Firm Q/Q Growth	0.00%	2.50%	-9.02%
Invested Capital Q/Q Growth	131.49%	-158.11%	122.64%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.18%	100.13%
Interest Burden Percent	96.93%	89.88%	90.20%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-33.78%	-36.26%	-46.01%
Cash Return on Invested Capital (CROIC)	-992.22%	0.00%	-63,405.74%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-33.78%	-36.26%	-46.01%
Return on Equity Simple (ROE_SIMPLE)	-30.05%	-33.83%	-57.19%
Net Operating Profit after Tax (NOPAT)	-42	-59	-67
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-9.77%	-8.12%	-10.37%
Return On Investment Capital (ROIC_SIMPLE)	-	-26.34%	-44.27%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-61	-85	-96
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-59	-84	-95
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.57	1.50	2.70
Price to Tangible Book Value (P/TBV)	1.57	1.50	2.70
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.92	0.00	2,402.84
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.97	-0.99	-1.00
Leverage Ratio	1.10	1.14	1.16
Compound Leverage Factor	1.07	1.02	1.04
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	5.30	5.32	4.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	18.81	18.76	10.77
Quick Ratio	18.06	18.30	10.13
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-45	-52	-68
Operating Cash Flow to CapEx	-4,990.95%	-9,005.22%	-6,369.11%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	5.98	-1.09	0.11
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	2.88	-7.07	1.20
Enterprise Value (EV)	119	113	260
Market Capitalization	308	339	411
Book Value per Share	$6.67	$5.90	$3.04
Tangible Book Value per Share	$6.67	$5.90	$3.04
Total Capital	196	226	152
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-189	-226	-151
Capital Expenditures (CapEx)	1.09	0.71	1.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.59	-6.73	-5.38
Debt-free Net Working Capital (DFNWC)	186	219	146
Net Working Capital (NWC)	186	219	146
Net Nonoperating Expense (NNE)	17	17	20
Net Nonoperating Obligations (NNO)	-190	-227	-152
Total Depreciation and Amortization (D&A)	1.18	1.30	1.22
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.96)	($1.93)	($1.75)
Adjusted Weighted Average Basic Shares Outstanding	29.94M	39.62M	49.65M
Adjusted Diluted Earnings per Share	($1.96)	($1.93)	($1.75)
Adjusted Weighted Average Diluted Shares Outstanding	29.94M	39.62M	49.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.80M	49.50M	50.23M
Normalized Net Operating Profit after Tax (NOPAT)	-42	-59	-67
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-86.41%	-216.21%	-51.77%	-48.60%	-25.30%	-40.33%	-15.21%	-12.33%	-13.87%	-13.50%
EBIT Growth	-85.28%	-209.12%	-51.30%	-47.59%	-25.08%	-39.60%	-14.84%	-12.21%	-13.49%	-13.19%
NOPAT Growth	-80.49%	-209.16%	-51.78%	-46.76%	-27.61%	-40.71%	-14.76%	-12.26%	-13.39%	-12.21%
Net Income Growth	-79.92%	-42.33%	-36.08%	-35.87%	-16.42%	-33.65%	-12.82%	-11.14%	-13.67%	-16.73%
EPS Growth	98.09%	-100.76%	-4.55%	-4.35%	11.11%	1.92%	13.04%	14.58%	12.50%	-1.96%
Operating Cash Flow Growth	-23.82%	-49.04%	-7.97%	-37.80%	-43.15%	3.48%	-48.99%	-10.13%	0.84%	-37.76%
Free Cash Flow Firm Growth	-34.74%	0.00%	28.41%	24.95%	-18.44%	32.44%	-24.45%	-32.04%	-2.06%	-101.10%
Invested Capital Growth	11.66%	92.78%	-22.32%	-39.79%	-27.50%	-118.20%	-13.57%	-10.07%	-125.45%	109.92%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-19.44%	-7.57%	-10.57%	-4.60%	-0.71%	-20.48%	9.22%	-1.98%	-2.09%	-20.10%
EBIT Q/Q Growth	-19.07%	-7.56%	-10.41%	-4.37%	-0.91%	-20.05%	9.17%	-1.98%	-2.06%	-19.73%
NOPAT Q/Q Growth	-16.21%	-9.70%	-10.40%	-4.28%	-1.05%	-20.96%	9.97%	-2.01%	-2.06%	-19.70%
Net Income Q/Q Growth	-18.07%	-4.14%	-5.48%	-4.77%	-1.16%	-19.55%	10.96%	-3.20%	-3.47%	-22.77%
EPS Q/Q Growth	-17.39%	3.70%	11.54%	-4.35%	0.00%	-6.25%	21.57%	-2.50%	-2.44%	-23.81%
Operating Cash Flow Q/Q Growth	-1.24%	-67.41%	8.89%	10.77%	-5.18%	-12.88%	-40.63%	34.04%	5.30%	-56.83%
Free Cash Flow Firm Q/Q Growth	26.75%	-32.16%	21.75%	0.94%	-15.61%	24.62%	-44.16%	-5.10%	10.64%	-48.54%
Invested Capital Q/Q Growth	-57.19%	131.49%	-0.60%	-38.87%	-48.46%	-158.11%	572.08%	-36.39%	-114.59%	122.64%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.62%	100.23%	100.00%	100.20%	100.09%
Interest Burden Percent	97.05%	93.96%	89.77%	90.11%	90.33%	89.40%	87.98%	89.24%	90.29%	92.69%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-54.02%	-33.78%	-39.46%	-46.17%	-53.11%	-36.26%	-40.43%	-45.09%	-50.99%	-46.01%
Cash Return on Invested Capital (CROIC)	0.00%	-992.22%	-663.59%	-1,012.27%	-2,411.47%	0.00%	-1,094.69%	-1,820.92%	0.00%	-63,405.74%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	4.32%	-33.78%	-39.46%	-46.17%	-53.11%	-36.26%	-40.43%	-45.09%	-50.99%	-46.01%
Return on Equity Simple (ROE_SIMPLE)	-46.79%	0.00%	-35.17%	-40.99%	-46.69%	0.00%	-37.67%	-42.14%	-47.64%	0.00%
Net Operating Profit after Tax (NOPAT)	-11	-12	-14	-14	-14	-17	-16	-16	-16	-19
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.80%	-2.50%	-2.51%	-2.87%	-3.18%	-2.30%	-2.16%	-2.51%	-2.94%	-3.36%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-7.68%	-	-	-	-12.81%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-16	-18	-19	-20	-20	-25	-22	-23	-23	-28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-16	-17	-19	-20	-20	-24	-22	-22	-23	-28
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.61	1.57	1.95	2.80	2.26	1.50	1.86	1.96	2.53	2.70
Price to Tangible Book Value (P/TBV)	4.61	1.57	1.95	2.80	2.26	1.50	1.86	1.96	2.53	2.70
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	161.99	19.92	29.80	83.83	103.28	0.00	36.13	57.23	0.00	2,402.84
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.98	-0.97	-0.96	-0.97	-0.98	-0.99	-0.97	-0.98	-1.00	-1.00
Leverage Ratio	1.17	1.10	1.10	1.11	1.21	1.14	1.13	1.15	1.18	1.16
Compound Leverage Factor	1.14	1.04	0.98	1.00	1.09	1.02	1.00	1.02	1.07	1.07
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	9.94	5.94	7.30	9.49	5.84	6.10	7.78	6.95	6.88	5.65
Noncontrolling Interest Sharing Ratio	108.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.63	18.81	22.09	18.69	14.13	18.76	21.97	18.54	12.47	10.77
Quick Ratio	11.19	18.06	21.40	18.21	13.68	18.30	20.99	17.77	11.85	10.13
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-12	-15	-12	-12	-14	-10	-15	-16	-14	-21
Operating Cash Flow to CapEx	-17,079.37%	-5,031.56%	-13,235.48%	-8,227.53%	-17,114.44%	-5,484.86%	-11,643.81%	-4,001.99%	-4,478.89%	-8,010.70%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2.59	5.98	5.95	3.64	1.87	-1.09	5.14	3.27	-0.48	0.11
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.27	2.88	-1.71	-2.40	-0.71	-7.07	-0.81	-0.37	-2.35	1.20
Enterprise Value (EV)	419	119	177	305	194	113	186	187	268	260
Market Capitalization	530	308	351	467	343	339	389	375	442	411
Book Value per Share	$3.93	$6.67	$4.77	$4.40	$3.97	$5.90	$4.22	$3.86	$3.52	$3.04
Tangible Book Value per Share	$3.93	$6.67	$4.77	$4.40	$3.97	$5.90	$4.22	$3.86	$3.52	$3.04
Total Capital	115	196	180	166	152	226	209	191	175	152
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-112	-189	-174	-162	-149	-226	-203	-187	-174	-151
Capital Expenditures (CapEx)	0.06	0.36	0.12	0.18	0.09	0.32	0.21	0.40	0.34	0.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.76	-2.59	-2.53	-4.72	-6.08	-6.73	-0.29	-2.37	-5.61	-5.38
Debt-free Net Working Capital (DFNWC)	106	186	171	157	143	219	203	185	169	146
Net Working Capital (NWC)	106	186	171	157	143	219	203	185	169	146
Net Nonoperating Expense (NNE)	4.66	4.23	3.86	4.11	4.17	4.78	4.09	4.40	4.78	6.37
Net Nonoperating Obligations (NNO)	-112	-190	-174	-163	-150	-227	-204	-188	-175	-152
Total Depreciation and Amortization (D&A)	0.30	0.32	0.33	0.30	0.34	0.32	0.31	0.31	0.31	0.29
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.54)	($0.52)	($0.46)	($0.48)	($0.48)	($0.51)	($0.40)	($0.41)	($0.42)	($0.52)
Adjusted Weighted Average Basic Shares Outstanding	29.27M	29.94M	37.78M	37.86M	38.19M	39.62M	49.45M	49.55M	49.66M	49.65M
Adjusted Diluted Earnings per Share	($0.54)	($0.52)	($0.46)	($0.48)	($0.48)	($0.51)	($0.40)	($0.41)	($0.42)	($0.52)
Adjusted Weighted Average Diluted Shares Outstanding	29.27M	29.94M	37.78M	37.86M	38.19M	39.62M	49.45M	49.55M	49.66M	49.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	29.33M	37.80M	37.80M	38.20M	38.26M	49.50M	49.54M	49.61M	49.95M	50.23M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-12	-14	-14	-14	-17	-16	-16	-16	-19
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Aura Biosciences' Financials

When does Aura Biosciences's fiscal year end?

According to the most recent income statement we have on file, Aura Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Aura Biosciences' net income changed over the last 2 years?

Aura Biosciences' net income appears to be on an upward trend, with a most recent value of -$86.92 million in 2024, rising from -$58.76 million in 2022. The previous period was -$76.41 million in 2023.

What is Aura Biosciences's operating income?

Aura Biosciences's total operating income in 2024 was -$96.12 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $96.12 million

How has Aura Biosciences revenue changed over the last 2 years?

Over the last 2 years, Aura Biosciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Aura Biosciences have?

Aura Biosciences' total liabilities were at $30.53 million at the end of 2024, a 4.5% increase from 2023, and a 7.7% increase since 2022.

How much cash does Aura Biosciences have?

In the past 2 years, Aura Biosciences' cash and equivalents has ranged from $31.69 million in 2024 to $121.58 million in 2022, and is currently $31.69 million as of their latest financial filing in 2024.

How has Aura Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Aura Biosciences' book value per share changed from 6.67 in 2022 to 3.04 in 2024, a change of -54.4%.

Related Companies

This page (NASDAQ:AURA) was last updated on 4/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Financials

Frequently Asked Questions About Aura Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Financials

Annual Income Statements for Aura Biosciences

Quarterly Income Statements for Aura Biosciences

Annual Cash Flow Statements for Aura Biosciences

Quarterly Cash Flow Statements for Aura Biosciences

Annual Balance Sheets for Aura Biosciences

Quarterly Balance Sheets for Aura Biosciences

Annual Metrics and Ratios for Aura Biosciences

Quarterly Metrics and Ratios for Aura Biosciences

Frequently Asked Questions About Aura Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools